Shares of Nektar Therapeutics (NKTR) more than doubled on Tuesday afternoon after the company announced that its mid-stage study evaluating Rezpegaldesleukin in atopic dermatitis demonstrated ...

Nektar’s shares have surged more than twofold after a Phase IIb study of its atopic dermatitis (AD) therapy rezpegaldesleukin (rezpeg) successfully met its primary and key secondary endpoints.

The analysts might have been a bit too bullish on Nektar Therapeutics (NASDAQ:NKTR), given that the company fell short of expectations when it released its quarterly results last week. Statutory ...

Nektar Therapeutics (NASDAQ: NKTR) stock is up around 150% in today’s trading session following the recently announced positive results from its Phase 2b REZOLVE-AD study of rezpegaldesleukin ...

Nektar (NKTR) gains on positive new data for its pipeline candidate, rezpegaldesleukin, evaluated from an early-stage study for treating atopic dermatitis.

Nektar: Q1 Earnings SnapshotSAN FRANCISCO — SAN FRANCISCO — Nektar Therapeutics (NKTR) on Thursday reported a loss of $50.9 million in its first quarter.

Nektar's longtime leader is trying to chart a new course for company after drug-test stumbles.

Nektar joined a wave of micro-cap biotechnology stocks surging after promising clinical trial results. And two Wall Street analysts believe shares could go even higher.

Nektar Therapeutics NKTR shares rallied late Monday after the biotech drug maker said it was cutting staff by 60% in San Francisco, where the company is based, and shifting its focus to immunology ...

Nektar announced that the ISLAND study of rezpeg in lupus failed to meet its primary endpoint. Read why pharma giant Lilly may walk away from the company's program.

Nektar.ai wants to solve the problem of data leakage with its sales productivity platform, which helps SaaS revenue teams manage info. % ...

Nektar Therapeutics has accused "former collaborator" Eli Lilly of botching the analysis of data from phase 1b trials in eczema and psoriasis.